While hepatitis C (HCV) currently remains the leading indication for liver transplant in Australia and New Zealand, non-alcoholic steatohepatitis (NASH) is expected to eventually take over given the drivers of overweight, obesity and diabetes. NASH currently sits third behind both HCV and alcoholic liver disease. A review of more than 5,000 adults activated for liver ...
Already a member?
Enter your email to keep reading.